Bionano Genomics (BNGO) COO discloses 15,000-share stock option at $1.12
Rhea-AI Filing Summary
Bionano Genomics, Inc. reports that Chief Operating Officer Mark Oldakowski beneficially owns a stock option giving the right to buy 15,000 shares of Common Stock at an exercise price of $1.12 per share. The option expires on August 2, 2036. According to the equity plan footnote, the shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case conditioned on the executive’s Continuous Service, as defined in the company’s 2018 plan. The position is reported as direct ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
OLDAKOWSKI MARK
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,000 shares (Direct)
Footnotes (1)
- F1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
Key Figures
Option Underlying Shares: 15,000 shares
Exercise Price: $1.12 per share
Option Expiration: August 2, 2036
+1 more
4 metrics
Option Underlying Shares
15,000 shares
Underlying Common Stock for COO stock option holding
Exercise Price
$1.12 per share
Strike price of COO stock option over 15,000 shares
Option Expiration
August 2, 2036
Expiration date of reported stock option position
Vesting Schedule
50% on each of first and second anniversaries
Vesting conditioned on Continuous Service under the 2018 Plan
Key Terms
Stock Option (Right to Buy), Continuous Service, underlying security, 2018 Plan
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Continuous Service financial
"subject to the Reporting Person's Continuous Service through each vesting date"
underlying security financial
"underlying_security_title: Common Stock; underlying_security_shares: 15000.0000"
2018 Plan financial
"Continuous Service (as defined in the Company's 2018 Plan)"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider position did BNGO’s COO report in this Form 3 filing?
Bionano Genomics’ COO Mark Oldakowski reported beneficial ownership of a stock option to buy 15,000 shares of Common Stock at an exercise price of $1.12 per share, expiring on August 2, 2036.
What is the strike price and size of the COO’s option position in BNGO?
The COO’s disclosed derivative position is a stock option over 15,000 underlying shares of Common Stock with an exercise price of $1.12 per share. This position is reported as directly owned.
How does the BNGO COO’s stock option reported on Form 3 vest?
The option vests 50% of the total on each of the first and second anniversaries of the vesting commencement date. Each vesting tranche is subject to the executive’s Continuous Service as defined in the company’s 2018 Plan.
When does the BNGO COO’s reported stock option expire?
The reported stock option position for Bionano Genomics’ COO expires on August 2, 2036. After this expiration date, any unexercised portion of the 15,000-share option would no longer be exercisable under the stated terms.
Is the BNGO COO’s stock option held directly or indirectly?
The filing classifies the COO’s stock option as direct ownership. This means the 15,000-share option position over Bionano Genomics Common Stock is reported as directly held, rather than through a trust, fund, or other indirect entity.